| Alogliptin | diabetes type 2, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amputations | no data | | nephropathy | no data | | cardiovascular events | 0.96 [0.81 1.13] | p=1.00 | 0 | 5380 | 1 | EXAMINE, | | Cardiovascular death | 0.85 [0.66 1.10] | p=1.00 | 0 | 5380 | 1 | EXAMINE, | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | retinopathy | no data | | microvascular events | no data | | hospitalisation for heart failure | no data | | All cause death | 0.88 [0.71 1.09] | p=1.00 | 0 | 5380 | 1 | EXAMINE, |
| Trial | Studied treatment | Control | Patients |
|---|
| EXAMINE, 2013 | alogliptin | placebo | patients with type 2 diabetes and either an acute myocardial
infarction or unstable angina requiring hospitalization within the previous 15
to 90 days |
| |
| Linagliptin | diabetes type 2, in all type of patients | vs glimepiride | cardiovascular events by 54% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amputations | no data | | nephropathy | no data | | cardiovascular events | 0.46 [0.23 0.91] | p=0.04 | 0 | 1551 | 1 | CAROLINA, | | Cardiovascular death | 1.00 [0.14 7.14] | p=1.00 | 0 | 1551 | 1 | CAROLINA, | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | retinopathy | no data | | microvascular events | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| CAROLINA, 2012 | linagliptin | glimepiride 1-4 mg QD | patients with type 2 diabetes at elevated cardiovascular risk receiving usual care |
| |
| Saxagliptin | diabetes type 2, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amputations | no data | | nephropathy | no data | | cardiovascular events | 1.00 [0.89 1.12] | p=1.00 | 0 | 16492 | 1 | SAVOR TIMI, | | Cardiovascular death | 1.03 [0.87 1.22] | p=1.00 | 0 | 16492 | 1 | SAVOR TIMI, | | myocardial infarction (fatal and non fatal) | 0.95 [0.80 1.12] | p=1.00 | 0 | 16492 | 1 | SAVOR TIMI, | | stroke (fatal and non fatal) | 1.11 [0.88 1.40] | p=1.00 | 0 | 16492 | 1 | SAVOR TIMI, | | retinopathy | no data | | microvascular events | no data | | hospitalisation for heart failure | no data | | All cause death | 1.11 [0.97 1.28] | p=1.00 | 0 | 16492 | 1 | SAVOR TIMI, |
| Trial | Studied treatment | Control | Patients |
|---|
| SAVOR TIMI, 2013 | saxagliptin | placebo | patients with type 2 diabetes who had a history of,
or were at risk for, cardiovascular events |
| |
| Sitagliptin | diabetes type 2, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amputations | no data | | nephropathy | no data | | cardiovascular events | 0.99 [0.89 1.10] | p=1.00 | 0 | 14671 | 1 | TECOS, | | Cardiovascular death | 1.03 [0.89 1.19] | p=1.00 | 0 | 14671 | 1 | TECOS, | | myocardial infarction (fatal and non fatal) | 0.95 [0.81 1.11] | p=1.00 | 0 | 14671 | 1 | TECOS, | | stroke (fatal and non fatal) | 0.97 [0.79 1.19] | p=1.00 | 0 | 14671 | 1 | TECOS, | | retinopathy | no data | | microvascular events | no data | | hospitalisation for heart failure | no data | | All cause death | 1.01 [0.90 1.14] | p=1.00 | 0 | 14671 | 1 | TECOS, |
| Trial | Studied treatment | Control | Patients |
|---|
| TECOS, 2015 | sitagliptin phosphate, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily | placebo | patients with Type 2 Diabetes Mellitus having a history of cardiovascular disease and a hemoglobin A1c (HbA1c) of 6.5% to 8.0% |
| |
| Exenatide | diabetes type 2, in all type of patients | vs placebo | cardiovascular events by 9% fully demonstrated All cause death by 14% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amputations | no data | | nephropathy | no data | | cardiovascular events | 0.91 [0.83 1.00] | p=0.04 | 0 | 14752 | 1 | EXSCEL, | | Cardiovascular death | 0.88 [0.76 1.02] | p=1.00 | 0 | 14752 | 1 | EXSCEL, | | myocardial infarction (fatal and non fatal) | 0.97 [0.85 1.10] | p=1.00 | 0 | 14752 | 1 | EXSCEL, | | stroke (fatal and non fatal) | 0.85 [0.70 1.03] | p=1.00 | 0 | 14752 | 1 | EXSCEL, | | retinopathy | no data | | microvascular events | no data | | hospitalisation for heart failure | 0.94 [0.78 1.13] | p=1.00 | 0 | 14752 | 1 | EXSCEL, | | All cause death | 0.86 [0.77 0.97] | p=0.04 | 0 | 14752 | 1 | EXSCEL, |
| Trial | Studied treatment | Control | Patients |
|---|
| EXSCEL, 2017 | subcutaneous injections of extended-release exenatide at a dose of 2 mg once weakly | placebo | patients with type 2 diabetes, with or without previous cardiovascular disease |
| |
| Liraglutide | diabetes type 2, in all type of patients | vs placebo | cardiovascular events by 12% fully demonstrated nephropathy by 20% suggested Cardiovascular death by 21% suggested microvascular events by 15% suggested All cause death by 15% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amputations | no data | | nephropathy | 0.80 [0.67 0.94] | p=0.04 | 0 | 9340 | 1 | LEADER, | | cardiovascular events | 0.88 [0.78 0.99] | p=0.04 | 0 | 9340 | 1 | LEADER, | | Cardiovascular death | 0.79 [0.66 0.95] | p=0.04 | 0 | 9340 | 1 | LEADER, | | myocardial infarction (fatal and non fatal) | 0.86 [0.73 1.01] | p=1.00 | 0 | 9340 | 1 | LEADER, | | stroke (fatal and non fatal) | 0.87 [0.71 1.07] | p=1.00 | 0 | 9340 | 1 | LEADER, | | retinopathy | 1.15 [0.87 1.53] | p=1.00 | 0 | 9340 | 1 | LEADER, | | microvascular events | 0.85 [0.74 0.99] | p=0.04 | 0 | 9340 | 1 | LEADER, | | hospitalisation for heart failure | 0.88 [0.73 1.06] | p=1.00 | 0 | 9340 | 1 | LEADER, | | All cause death | 0.85 [0.74 0.98] | p=0.04 | 0 | 9340 | 1 | LEADER, |
| Trial | Studied treatment | Control | Patients |
|---|
| LEADER, 2016 | Maximum dose of 1.8 mg liraglutide, injected subcutaneously once daily | placebo | subjects with type 2 diabetes |
| |
| Lixisenatide | diabetes type 2, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amputations | no data | | nephropathy | no data | | cardiovascular events | 1.02 [0.89 1.17] | p=1.00 | 0 | 6068 | 1 | ELIXA, | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | retinopathy | no data | | microvascular events | no data | | hospitalisation for heart failure | no data | | All cause death | 0.94 [0.78 1.13] | p=1.00 | 0 | 6068 | 1 | ELIXA, |
| Trial | Studied treatment | Control | Patients |
|---|
| ELIXA, | lixisenatide | placebo | patients with T2DM and a recent ACS event |
| |
| Semaglutide | diabetes type 2, in all type of patients | vs placebo | cardiovascular events by 26% fully demonstrated nephropathy by 36% suggested retinopathy by 76% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amputations | no data | | nephropathy | 0.64 [0.46 0.89] | p=0.04 | 0 | 3297 | 1 | SUSTAIN 6, | | cardiovascular events | 0.74 [0.58 0.95] | p=0.04 | 0 | 3297 | 1 | SUSTAIN 6, | | Cardiovascular death | 0.98 [0.65 1.48] | p=1.00 | 0 | 3297 | 1 | SUSTAIN 6, | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | retinopathy | 1.76 [1.11 2.79] | p=0.04 | 0 | 3297 | 1 | SUSTAIN 6, | | microvascular events | no data | | hospitalisation for heart failure | no data | | All cause death | 1.05 [0.74 1.49] | p=1.00 | 0 | 3297 | 1 | SUSTAIN 6, |
| Trial | Studied treatment | Control | Patients |
|---|
| SUSTAIN 6, 2016 | once-weekly semaglutide (0.5 mg or 1.0 mg) | placebo | patients with type 2 diabetes who were on a standardcare
regimen |
| |
| Glargine | diabetes type 2, in all type of patients | vs control | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amputations | 0.89 [0.60 1.32] | p=1.00 | 0 | 12537 | 1 | ORIGINE, | | nephropathy | no data | | cardiovascular events | 1.02 [0.94 1.11] | p=1.00 | 0 | 12537 | 1 | ORIGINE, | | Cardiovascular death | 1.00 [0.89 1.13] | p=1.00 | 0 | 12537 | 1 | ORIGINE, | | myocardial infarction (fatal and non fatal) | 1.02 [0.88 1.19] | p=1.00 | 0 | 12537 | 1 | ORIGINE, | | stroke (fatal and non fatal) | 1.03 [0.88 1.20] | p=1.00 | 0 | 12537 | 1 | ORIGINE, | | retinopathy | no data | | microvascular events | 0.97 [0.90 1.05] | p=1.00 | 0 | 12537 | 1 | ORIGINE, | | hospitalisation for heart failure | 0.90 [0.77 1.05] | p=1.00 | 0 | 12537 | 1 | ORIGINE, | | All cause death | 0.98 [0.89 1.07] | p=1.00 | 0 | 12537 | 1 | ORIGINE, |
| Trial | Studied treatment | Control | Patients |
|---|
| ORIGINE, 2012 | insulin glargine (with a target fasting blood glucose level of ¡Ü95 mg per deciliter | standard care | with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes |
| |
| Aleglitazar | diabetes type 2, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amputations | no data | | nephropathy | no data | | cardiovascular events | 0.96 [0.83 1.11] | p=1.00 | 0 | 7226 | 1 | ALECARDIO, | | Cardiovascular death | 1.15 [0.88 1.51] | p=1.00 | 0 | 7226 | 1 | ALECARDIO, | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | retinopathy | no data | | microvascular events | no data | | hospitalisation for heart failure | no data | | All cause death | 1.08 [0.85 1.37] | p=1.00 | 0 | 7226 | 1 | ALECARDIO, |
| Trial | Studied treatment | Control | Patients |
|---|
| ALEPREVENT, | aleglitazar 150 ìg | placebo | patients with T2D or prediabetes with established, stable CV disease | | ALECARDIO, 2014 | aleglitazar 150 ìg daily | placebo | patients hospitalized for ACS (myocardial infarction or unstable angina) with type 2 diabetes |
| |
| Canagliflozin | diabetes type 2, in all type of patients | vs placebo | cardiovascular events by 14% fully demonstrated Amputations by 97% suggested nephropathy by 40% suggested hospitalisation for heart failure by 33% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amputations | 1.97 [1.41 2.75] | p=0.04 | 0 | 10142 | 1 | CANVAS, | | nephropathy | 0.60 [0.47 0.77] | p=0.04 | 0 | 10142 | 1 | CANVAS, | | cardiovascular events | 0.86 [0.76 0.98] | p=0.04 | 0 | 10142 | 1 | CANVAS, | | Cardiovascular death | 0.87 [0.72 1.06] | p=1.00 | 0 | 10142 | 1 | CANVAS, | | myocardial infarction (fatal and non fatal) | 0.89 [0.73 1.09] | p=1.00 | 0 | 10142 | 1 | CANVAS, | | stroke (fatal and non fatal) | 0.87 [0.69 1.09] | p=1.00 | 0 | 10142 | 1 | CANVAS, | | retinopathy | no data | | microvascular events | no data | | hospitalisation for heart failure | 0.67 [0.52 0.87] | p=0.04 | 0 | 10142 | 1 | CANVAS, | | All cause death | 0.87 [0.74 1.02] | p=1.00 | 0 | 10142 | 1 | CANVAS, |
| Trial | Studied treatment | Control | Patients |
|---|
| CANVAS, 2017 | canagliflozin | placebo | participants with type 2 diabetes and high cardiovascular risk |
| |
| Dapagliflozin | diabetes type 2, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amputations | no data | | nephropathy | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | retinopathy | no data | | microvascular events | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| DECLARE TIMI 58, 2018 | Dapagliflozin | | adults with T2D at risk of CV events, including patients with multiple CV risk factors or established CV disease |
| |
| Empagliflozin | diabetes type 2, in all type of patients | vs placebo | cardiovascular events by 14% fully demonstrated Cardiovascular death by 38% suggested hospitalisation for heart failure by 35% suggested All cause death by 32% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amputations | no data | | nephropathy | no data | | cardiovascular events | 0.86 [0.74 0.99] | p=0.04 | 0 | 7020 | 1 | EMPA-REG OUTCOME, | | Cardiovascular death | 0.62 [0.49 0.78] | p=0.04 | 0 | 7020 | 1 | EMPA-REG OUTCOME, | | myocardial infarction (fatal and non fatal) | 0.87 [0.70 1.09] | p=1.00 | 0 | 7020 | 1 | EMPA-REG OUTCOME, | | stroke (fatal and non fatal) | 1.18 [0.89 1.56] | p=1.00 | 0 | 7020 | 1 | EMPA-REG OUTCOME, | | retinopathy | no data | | microvascular events | no data | | hospitalisation for heart failure | 0.65 [0.50 0.85] | p=0.04 | 0 | 7020 | 1 | EMPA-REG OUTCOME, | | All cause death | 0.68 [0.57 0.82] | p=0.04 | 0 | 7020 | 1 | EMPA-REG OUTCOME, |
| Trial | Studied treatment | Control | Patients |
|---|
| EMPA-REG OUTCOME, 2015 | 10 mg or 25 mg of empagliflozin once daily | placebo | patients
with type 2 diabetes at high cardiovascular risk |
| |
| Pioglitazone | diabetes type 2, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amputations | no data | | nephropathy | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | retinopathy | no data | | microvascular events | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| PROACTIVE, | oral pioglitazone titrated from 15 mg to 45 mg | placebo | patients with type 2 diabetes who had evidence of macrovascular disease. | | IRIS, 2016 | | | |
| |
